Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review
- PMID: 37659966
- PMCID: PMC10844924
- DOI: 10.1016/j.clml.2023.08.008
Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review
Abstract
We performed a systematic review of the literature investigating the demographic and insurance-related factors linked to disparities in multiple myeloma (MM) care patterns in the United States from 2003 to 2021. Forty-six observational studies were included. Disparities in MM care patterns were reported based on patient race in 76% of studies (34 out of 45 that captured race as a study variable), ethnicity in 60% (12 out of 20), insurance in 77% (17 out of 22), and distance from treating facility, urbanicity, or geographic region in 62% (13 out of 21). A smaller proportion of studies identified disparities in MM care patterns based on other socioeconomic characteristics, with 36% (9 out of 25) identifying disparities based on income estimate or employment status and 43% (6 out of 14) based on language barrier or education-related factors. Sociodemographic characteristics are frequently associated with disparities in care for individuals diagnosed with MM. There is a need for further research regarding modifiable determinants to accessing care such as insurance plan design, patient out-of-pocket costs, preauthorization criteria, as well as social determinants of health. This information can be used to develop actionable strategies for reducing MM health disparities and enhancing timely and high-quality MM care.
Keywords: Health equity; Health insurance; Hematologic malignancies; Race; Social determinants of health.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure All authors declare no relevant conflicts of interest related to this manuscript.
Similar articles
-
Multiple myeloma care, treatment patterns, and treatment durations in academic and community care settings.Future Oncol. 2025 Jun;21(15):1905-1918. doi: 10.1080/14796694.2025.2504318. Epub 2025 May 21. Future Oncol. 2025. PMID: 40400295 Free PMC article.
-
Guided tissue regeneration for periodontal infra-bony defects.Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001724. doi: 10.1002/14651858.CD001724.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2019 May 29;5:CD001724. doi: 10.1002/14651858.CD001724.pub3. PMID: 16625546 Updated.
-
Determinants of demand for total hip and knee arthroplasty: a systematic literature review.BMC Health Serv Res. 2012 Jul 30;12:225. doi: 10.1186/1472-6963-12-225. BMC Health Serv Res. 2012. PMID: 22846144 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Financial arrangements for health systems in low-income countries: an overview of systematic reviews.Cochrane Database Syst Rev. 2017 Sep 11;9(9):CD011084. doi: 10.1002/14651858.CD011084.pub2. Cochrane Database Syst Rev. 2017. PMID: 28891235 Free PMC article.
Cited by
-
High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma.JCO Oncol Pract. 2025 May 12:OP2400978. doi: 10.1200/OP-24-00978. Online ahead of print. JCO Oncol Pract. 2025. PMID: 40354593
-
A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast.Sci Rep. 2025 Jan 16;15(1):2204. doi: 10.1038/s41598-024-83630-x. Sci Rep. 2025. PMID: 39820043 Free PMC article.
-
Disparities in time to treatment with oral antimyeloma medications.Blood Cancer J. 2024 Aug 23;14(1):142. doi: 10.1038/s41408-024-01128-1. Blood Cancer J. 2024. PMID: 39179575 Free PMC article.
-
Closing the gaps: Tackling myeloma inequities in Latin America.Hematol Transfus Cell Ther. 2025 Jul-Sep;47(3):103848. doi: 10.1016/j.htct.2025.103848. Epub 2025 Jun 5. Hematol Transfus Cell Ther. 2025. PMID: 40479959 Free PMC article. No abstract available.
-
Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.Blood Cancer J. 2024 Aug 27;14(1):149. doi: 10.1038/s41408-024-01129-0. Blood Cancer J. 2024. PMID: 39191731 Free PMC article. Review.
References
-
- National Cancer Institute. Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts: Myeloma. Published 2022. Accessed March 13, 2022. https://seer.cancer.gov/statfacts/html/mulmy.html
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical